Overview


According to FutureWise analysis, the market for Fascioliasis is expected to grow with a CAGR of 4.52% over the forecast period 2024-2032, and reach a market value of US$ 0.51 Billion by 2031. 

Fascioliasis, or liver fluke infection, is a parasitic ailment resulting from trematodes belonging to the genus Fasciola. It impacts various mammals, including humans, and is chiefly contracted through ingesting tainted water plants or aquatic vegetation. The life cycle of the Fasciola parasite involves several stages. It begins in freshwater environments, where adult flukes release eggs that hatch into miracidia larvae. These miracidia then infect specific freshwater snails, undergoing further development before emerging as free-swimming cercariae. These cercariae encyst on aquatic plants, forming metacercariae, the infective stage for mammals.

The clinical presentation of fascioliasis can vary widely, ranging from mild or asymptomatic cases to severe, potentially life-threatening conditions. Chronic infections can lead to complications like liver abscesses, cholangitis, and even liver failure in extreme cases. Diagnosis of fascioliasis involves a combination of clinical evaluation, blood tests to detect specific antibodies or antigens, and imaging techniques like ultrasound to visualize liver abnormalities. Treatment involves using anthelminthic medications, such as triclabendazole, the drug of choice for fascioliasis. Preventative measures include ensuring the thorough cooking of aquatic plants and using safe drinking water sources. Controlling livestock grazing near contaminated water bodies is also crucial. In areas endemic to fascioliasis.

FutureWise Market Research has published a report that provides an insightful analysis of Fascioliasis Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Fascioliasis Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Novartis AG,
  • AMGIS Lifescience Ltd.
  • Romark, L.C.
  • AbbVie Inc.
  • Merck KGaA 
  • AdvaCare Pharma
  • Intas Pharmaceuticals Ltd. 
  • Procyon Life Sciences 
  • Adroit Pharmachem Pvt Ltd. 
  • Sun Pharmaceutical Industries Ltd.
  • RV Lifesciences Limited
  • Grampus Laboratories
  • Janssen Pharmaceuticals, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Increasing awareness about the risk factors, transmission methods, and preventive measures for fascioliasis can drive efforts to prevent and treat the disease.  Implementing effective veterinary and agricultural practices, such as deworming livestock and proper pasture management, can help reduce the prevalence of Fasciola parasites in animals, reducing the risk of human infection. Advanced research and development into the biology, epidemiology, and treatment of Fasciola parasites can lead to the integration of more effective prevention and treatment methods. Governmental agencies and non-governmental organizations (NGOs) may implement programs to control fascioliasis through public health interventions, educational campaigns, and veterinary support.

However, managing fascioliasis may be challenging in regions with limited access to healthcare facilities and medical resources, potentially leading to underreporting and inadequate care. Environmental conditions, such as water contamination and suitable intermediate hosts (snails), can contribute to the persistence and spread of Fasciola parasites, making prevention efforts more challenging. Changes in climate patterns, including temperature and precipitation, can influence the distribution and prevalence of Fasciola parasites, potentially leading to shifts in affected regions and restraining market growth.

By Drug

  • Triclabendazole
  • Albendazole
  • Nitazoxanide

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the presence of refined healthcare infrastructure and the prominent presence of key industry players. Conversely, the Asia-Pacific region is poised for substantial expansion in the forecast period due to the high adoption of fascioliasis drugs, dependency on livestock as occupation, increased patient awareness level, and high prevalence of leishmaniasis. 

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Fascioliasis Market By Drug, By Distribution Channel, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Fascioliasis Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Fascioliasis Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Fascioliasis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Fascioliasis Market, By Drug Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Triclabendazole
        2. Albendazole
        3. Nitazoxanide

  • 8.  Fascioliasis Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 9.  North America Fascioliasis Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 10.  Latin America Fascioliasis Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 11.  Europe Fascioliasis Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 12.  Asia Pacific Fascioliasis Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 13.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 14.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1.  Novartis AG
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. AMGIS Lifescience Ltd
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Romark, L.C.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. AbbVie Inc.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Merck KGaA
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. AdvaCare Pharma
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Intas Pharmaceuticals Ltd.
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Procyon Life Sciences
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Adroit Pharmachem Pvt Ltd.
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Sun Pharmaceutical Industries Ltd.
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. RV Lifesciences Limited
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Grampus Laboratories
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Janssen Pharmaceuticals, Inc.
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
            administrations
        5. The overall economic slowdown of the developing and developed nations
       

  • 17.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients